HXL's Principal Activity is the research and development of plant-derived proteins and peptides for applications as human therapeutics.
|Bid / Ask||-|
|Volume (4w avg)|
|vs Sector (1yr)||-|
|vs ASX 200 (1yr)||-43.23%|
|ASX Rank||1,687 of 2,237|
|NTA per share||$0.00|
HXL is not covered by a major broker, or data from most recent compilation was omitted due to not meeting QA guidelines.
Hexima Limited (HXL) is a biotechnology company actively engaged in the research and development of plant-derived defensin peptides for applications as human therapeutics. Its lead product candidate, HXP124 applied in a topical formulation, is a potential new prescription treatment for toenail fungal infections (or onychomycosis). Hexima is currently conducting a 132 patient Australian phase IIb clinical trial of HXP124 for onychomycosis.
No incorporation details available.
|No dividends paid.|
See Upcoming Dividends for all ASX companies.
|Mr Steven Michael Skala||Alternate Director||Mar 2020||
Mr Steven Michael Skala
Mr Skala is Vice Chairman, Australia and New Zealand of Deutsche Bank AG. He retired from legal practice after almost 25 years experience in commercial law. Between 1985 and 2004 he was a partner of law firm, Arnold Bloch Leibler, and was Head of its Corporate and Commercial Practice for several years. He is a Director of the Australian Broadcasting Corporation, Deutsche Australia Limited, Wilson HTM Investment Group Limited, and The Centre for Independent Studies and he is Deputy Chairman of the General Sir John Monash Foundation. He is also Vice President of The Walter and Eliza Hall Institute for Medical Research and was previously Chairman of Film Australia Limited and The Australian Centre for Contemporary Arts and a director of Max Capital Group Limited and The Australian Ballet.
|Mr Michael Douglas Aldridge||Chief Executive Officer,Managing Director||May 2019||
Mr Michael Douglas Aldridge
Chief Executive Officer,Managing Director
Mr Aldridge most recently served as Senior Vice President, Corporate & Strategic Development of Codexis from October 2016 until August 2018. Prior to that, from January 2012 to September 2014, he served as Senior Vice President, Corporate Strategic Development for Questcor Pharmaceuticals, Inc., a publicly-traded biopharmaceutical company acquired by Mallinckrodt Pharmaceuticals in 2014. From May 2010 to September 2012, Mr Aldridge served as Chief Executive Officer and a member of the board of directors for Xenome Limited, a privately-held biopharmaceutical company headquartered in Australia. Between 2003 and 2009, he served as Chief Executive Officer and a member of the board of directors and a strategic consultant of Peplin, Inc., a publicly-traded drug development company acquired by LEO Pharma A/S in 2009. Prior to that, he held investment banking positions at various financial firms, including Wilson HTM Investment Group, Bear, Stearns & Co., Volpe, Brown, Whelan & Company and S.G. Warburg Group.
|Mr Scott Christian Robertson||Non-Executive Director||Nov 2018||
Mr Scott Christian Robertson
Mr Robertson is currently Chief Financial Officer at DiCE Molecules. Prior to DiCE Molecules, he served at DuPont where he was Business Development Director for DuPont Pioneer with responsibility for the business unit's crop genetics and precision agriculture M&A activity. He also held the position of portfolio manager with DuPont Ventures where he focused on strategic investment opportunities in production agriculture and the intersection of agriculture and downstream renewable technologies. Prior to joining DuPont, he was an investment professional at MPM Capital, a life sciences-dedicated venture capital fund, and before that a member of the Healthcare Investment Banking groups at Merrill Lynch & Co. and Thomas Weisel Partners. He is also a member of Risk Committee.
|Mr Justin Zhen Nan Yap||Non-Executive Director||Jul 2018||
Mr Justin Zhen Nan Yap
Mr Yap is a Non-Executive Director of CathRx Limited, an Australian medical device company commercialising cardiac electrophysiology catheters for the treatment of heart rhythm disorders. He is a Non-Executive Director of Wilhelm Integrated Solutions Pty Ltd, a distributor of integrated operating room technology to hospitals around Australia. Prior to this, he began his career in investment banking for Mosaic Risk Management Pty Ltd, a wholly owned subsidiary of Wilson HTM Limited specialising in derivatives risk management. He s also a member of Risk Committee.
|Dr Nicole Louise van der Weerden||Chief Operating Officer,Executive Director||Dec 2014||
Dr Nicole Louise van der Weerden
Chief Operating Officer,Executive Director
Dr van der Weerden has experience as she has led the gene discovery program for the Pioneer partnership on control of fungal diseases in corn. She led the Hexima team that identified the clinical opportunities for plant antifungal molecules and discovered and developed HXP124 for treatment of onychomycosis. He is also an inventor on nine patent applications. Her PhD research on the antifungal properties and mechanism of action of plant defensins led to the award of a prestigious Victoria Fellowship in 2006.
|Professor Marilyn Ann Anderson||Chief Science Officer,Executive Director||Nov 2010||
Professor Marilyn Ann Anderson
Chief Science Officer,Executive Director
Professor Anderson has over 40 years of experience in scientific research in the area of biochemistry and genetics. After completing a BSc Honours at The University of Melbourne and a PhD in Biochemistry at La Trobe University, Professor Anderson spent seven years in the United States working on diabetes at the University of Miami Florida, and molecular biology at Cold Spring Harbor Laboratory NY. She is an expert on antifungal and insecticidal molecules produced by plants. She is a Professor of Biochemistry at La Trobe University, and a member of the Australian Academy of Science Council. She was appointed an Officer of the Order of Australia in 2016 for distinguished service to science and higher education. She was a member of the La Trobe Council until 2017.
|Professor Jonathan Paul West||Non-Executive Director,Non-Executive Chairman||Nov 2005||
Professor Jonathan Paul West
Non-Executive Director,Non-Executive Chairman
Professor West was the founding Director of the Australian Innovation Research Centre. Prior to that, he taught for 18 years at the Harvard University Graduate School of Business Administration, where he was Associate Professor, founding Director of the Harvard University Life Sciences Initiative, and from 1998-1999 the Novartis Faculty Research Fellow. He has been Visiting Professor at Hitotsubashi University and the Nomura School of Advanced Management in Tokyo, Japan and Visiting Professor at the University de Paris IX-Dauphine, Sorbonne. Professor West was Chairman of the Asia Advisory Council of Bunge Ltd and has served as an advisor to other corporations and several Governments around the world, including in the life sciences field DuPont, Roche, Novartis, Syngenta and the J.R. Simplot Company, along with the Governments of Singapore, Japan, Hong Kong and France. He was a member of the Scientific Advisory Board of the Novartis Agricultural Discovery Institute in La Jolla, California. In Australia, he has served on the Prime Minister's Science, Engineering, Innovation Council's Working Group on Science and Technology in China and India and in 2006 was 'Eminent Thinker in Residence' with the Premier of NSW. Professor West is the non-executive chairman of Gowing Bros Limited and non-executive director of Boundary Bend Limited and the Hydration Pharmaceuticals Company Limited. He is also the Chairman of Risk committee.
|Ms Helen Molloy||Company Secretary,Finance Controller||N/A|
|Marilyn A Anderson||Chief Science Officer||N/A|
|Robyn L Heath||Senior Vice President Product Development||N/A|
The current holdings of HXL directors.
|Director||Last Notice||Direct Shares||Indirect Shares||Options||Convertibles|
|Nicole van der Weerden||16/12/2014||144,700||N/A||1,650,000||N/A|
A substantial shareholder is a person or entity that owns 5% or more of the voting shares in a company. Shares can be held through multiple entities, so the Substantial Shareholders list differs from the Top 20 Shareholders list.
Shareholding changes less than 1% do not require notification to the market. When all “Last Notice” dates are identical, it suggests that no (or minimal) change has occurred since the most recent Annual Report.
|Name||Last Notice||Total Shares||Shares Held (%)|
|Skala, Steven Michael||05/10/2010||4,167,467||5.14|
|Clarke, Adrienne Elizabeth||05/10/2010||5,417,919||6.68|
|G F Dan O Brien||05/10/2010||5,000,000||6.17|
|Oatley, Robert Ian||05/10/2010||6,102,180||7.53|
|Morgan, Hugh Matheson||05/10/2010||6,454,503||7.96|
|Clianth Pty Limited||05/10/2010||4,213,510||5.20|
12 month transaction history compiled from ASX announcements.
No buy transactions reported by Substantial Shareholders in the past 12 months.
12 month transaction history compiled from ASX announcements.
No sell transactions reported by Substantial Shareholders in the past 12 months.
All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.